A multi-dosing study of AB-423 in HBV patients
Phase of Trial: Phase II
Latest Information Update: 03 Aug 2017
At a glance
- Drugs AB 423 (Primary)
- Indications Hepatitis B
- Focus Therapeutic Use
- 03 Aug 2017 According to an Arbutus Biopharma Corporation media release, this trial is expected to initiate by the end of 2017.
- 10 May 2017 New trial record
- 04 May 2017 According to an Arbutus Biopharma media release, this study will initiate in 2H 2017.